BiotechTube
Sama Therapeutics

Sama Therapeutics

Cambridge, United States· Est.
sama.ac
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $33M

Overview

Sama Therapeutics is an AI-driven neuropsychiatry company developing a predictive biomarker platform, iMAGiNE™, to reshape brain health diagnostics and therapeutic development. The company integrates generative AI with computational neuroscience to create digital tools that de-risk clinical trials, assist providers in treatment selection, and empower individuals to track brain function. Founded in 2018, Sama operates as a private, likely pre-revenue platform company targeting a significant unmet need in mental health and neurology through a data-driven, transdiagnostic approach.

PsychiatryNeurology

Technology Platform

iMAGiNE™ predictive biomarker platform: A SaaS/Software-as-a-Medical-Device (SaMD) platform that fuses generative AI with computational neuroscience. It uses multimodal data (psychometrics, EEG/ECG, VR, LLMs) for deep phenotyping, causal inference, and digital twin creation to predict treatment response across psychiatric disorders and modalities (transprognostic).

Funding History

2
Total raised:$33M
Series A$25M
Seed$8M

Opportunities

The massive unmet need in mental health and the high failure rate of CNS drug trials create a strong demand for tools that can de-risk development and personalize treatment.
The growing acceptance of digital health and AI in medicine, alongside emerging markets in wellness and psychedelic therapy, provides multiple commercialization pathways for a validated platform.

Risk Factors

Key risks include the significant challenge of obtaining regulatory clearance for its AI/ML models as medical devices, the difficulty of commercial adoption by pharmaceutical companies and healthcare systems, and competition in the crowded digital mental health space.
As a pre-revenue company, it also faces financial runway risks.

Competitive Landscape

Sama competes in the broad digital mental health and AI-for-drug-development space. Competitors include other AI-powered biomarker companies (e.g., Alto Neuroscience, BlackThorn Therapeutics), digital therapeutic platforms for psychiatry, and large tech companies investing in health AI. Its claimed transprognostic, modality-agnostic approach is a key differentiator.

More companies in United States →